Short Interest in NeueHealth, Inc. (NYSE:NEUE) Increases By 33.7%

NeueHealth, Inc. (NYSE:NEUEGet Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 12,300 shares, an increase of 33.7% from the February 28th total of 9,200 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average daily trading volume, of 47,300 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada decreased their target price on shares of NeueHealth from $8.00 to $7.00 and set a “sector perform” rating for the company in a research report on Monday, December 9th.

Read Our Latest Report on NEUE

NeueHealth Stock Performance

Shares of NeueHealth stock traded down $0.16 on Tuesday, hitting $6.60. The company had a trading volume of 20,751 shares, compared to its average volume of 19,981. NeueHealth has a 1 year low of $3.79 and a 1 year high of $7.66. The stock has a 50 day moving average of $6.92 and a 200-day moving average of $6.09. The stock has a market capitalization of $54.68 million, a price-to-earnings ratio of -0.13 and a beta of 0.56.

NeueHealth (NYSE:NEUEGet Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($7.41) earnings per share for the quarter, missing the consensus estimate of ($2.29) by ($5.12). NeueHealth had a negative net margin of 36.28% and a negative return on equity of 6.40%. The company had revenue of $232.64 million for the quarter, compared to the consensus estimate of $261.80 million. Equities analysts anticipate that NeueHealth will post -9.13 earnings per share for the current year.

Insider Activity

In other news, CFO Jay Matushak sold 4,970 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.33, for a total transaction of $36,430.10. Following the completion of the sale, the chief financial officer now owns 17,747 shares in the company, valued at $130,085.51. The trade was a 21.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO George Lawrence Mikan III sold 31,798 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.33, for a total value of $233,079.34. Following the transaction, the chief executive officer now directly owns 146,539 shares in the company, valued at $1,074,130.87. The trade was a 17.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,033 shares of company stock worth $774,560 in the last three months. Company insiders own 64.30% of the company’s stock.

Hedge Funds Weigh In On NeueHealth

A hedge fund recently bought a new stake in NeueHealth stock. Virtu Financial LLC purchased a new position in NeueHealth, Inc. (NYSE:NEUEFree Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,232 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned 0.12% of NeueHealth at the end of the most recent quarter. Institutional investors and hedge funds own 63.88% of the company’s stock.

NeueHealth Company Profile

(Get Free Report)

NeueHealth, Inc, a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics.

See Also

Receive News & Ratings for NeueHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeueHealth and related companies with MarketBeat.com's FREE daily email newsletter.